QUANTA-CLOUD-TECHNOLOGY
30.5.2022 06:02:10 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, will showcase its cutting-edge High-performance Computing (HPC) and AI solutions with vertical applications at the ISC High Performance Conference 2022 , from May 29 to June 2 in Hamburg, Germany at Booth D412 . These unique solutions combine QCT’s advanced hardware infrastructures with software technologies to help build scalable, converged HPC and AI environments across many industries while shortening the time to implement projects so researchers can fully concentrate on their research.
QCT will showcase the following solutions and servers that drive faster time-to-value:
- QCT Platform on Demand (QPOD): QPOD is a workload-driven and purpose-built solution for academia, research institutes, or medical centers, fully integrated with hardware infrastructures, cluster deployment, monitoring and management tools to fulfill HPC and AI workloads. On top of the infrastructure, QCT has also worked with application ISVs to ensure the solution is pre-configured and pre-validated for HPC applications.
- High Performance Storage: Enabled by Intel® Optane™ persistent memory, Distributed Asynchronous Object Storage (DAOS) offers dramatic improvements to storage I/O to accelerate HPC, AI, analytics, and cloud projects. QCT’s advanced storage servers equipped with the DAOS open-source software-defined object store have also brought world-class IOPS and bandwidth as they have ranked on the IO500 and 10-Node Challenge during SC21.
- QuantaGrid D53X-1U: a 1U compute node server optimized by 3rd Gen Intel® Xeon® Scalable processors with built-in AI Accelerators and Intel® Optane™ persistent memory 200 series to propel DAOS and enable AI, HPC and virtualization workloads.
- QuantaGrid D53XQ-2U: a 2U server that benefits from DAOS fueled by Intel® Optane™ persistent memory on the Intel Xeon Scalable platform and equipped with acceleration card expansion slots to power AI, analytics, bioscience, HPC, and even cloud computing workloads.
For more information on QCT’s high-performance storage product line, join QCT’s speaking session titled “Innovative High-performance Storage for AI/HPC in the Exascale Era” at the HPC Solutions Forum (Hall H, Booth J901) on May 31 at 2:00 pm. Our Technical Manager and Solution Architect, Grover Hwang, will give a deep dive on using DAOS to achieve less I/O wait and lower latency when running real-world AI/HPC applications.
“QCT is excited to bring our latest HPC solutions built for compute and graphic-intensive workloads to ISC 2022,” said QCT President Mike Yang. “As an infrastructure builder, QCT leverages our robust R&D capabilities and strong software ecosystem support to tune our solutions all the way from hardware to the software stack, accelerating digital transformation in fields across weather forecasting, NGS, molecular dynamics and more.”
Visit QCT Booth D412 at ISC22 and http://www.qct.io to learn more.
About QCT
QCT is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. http://www.qct.io
Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005020/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
Seiden Law LLP States: Cambodian Businessman Leak Yim, Wrongfully Accused in Thailand, Seeks Redress in U.S. Court29.6.2026 06:00:00 CEST | Press release
Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gathering remedies, permitting an applicant to obtain evidence in the United States to assist international proceedings. Seiden Law, a U.S. law firm with significant experience in 1782 cases, has filed this application to compel production of documents and sworn testimony from persons in the U.S. that will shed light on the circumstances surrounding recent actions against Mr. Yim. “Mr. Yim and his young family are the apparent victims of guilt by association and political persecution,” said Robert Seiden,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom